Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
Generalized Myasthenia Gravis|gMG
DRUG: Ravulizumab
Serum Concentration of Ravulizumab, Day 1 predose through Week 18 predose|Serum Free C5 Concentration, Day 1 predose through Week 18 predose
Change From Baseline in The Quantitative Myasthenia Gravis (QMG) Total Score at Up to Week 18, Baseline, Up to Week 18|Change From Baseline in Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Total Score at Up to Week 18, Baseline, Up to Week 18|Change From Baseline in Myasthenia Gravis Composite (MGC) Score at Up to Week 18, Baseline, Up to Week 18|Change in Status from Week 10 in Myasthenia Gravis Foundation of America Postintervention Status (MGFA-PIS) as Assessed by the Investigator or Neurologist at Up to Week 18, Week 10, Up to Week 18|Change from Baseline in Neurology Quality of Life (Neuro QoL) Pediatric Fatigue Score at Up to Week 18, Participants ≥8 years of age will be evaluated., Baseline, Up to Week 18|Change from Baseline in Patient-reported Outcomes Measurement Information System (PROMIS) Parent Proxy - Fatigue Score at Up to Week 18, Participants \<8 years of age will be evaluated., Baseline, Up to Week 18|Number of Participants With ≥5-point Reduction Compared to Baseline in the QMG Total Score Over Time Through Week 18, Baseline through Week 18|Number of Participants With ≥3 point Reduction Compared to Baseline in the MG-ADL Total Score Over Time Through Week 18, Baseline through Week 18|Number of Participants That Improve or Remain Stable in QMG Total Score at Week 18 Compared to Baseline, Stable is defined as a ±5-point change from Baseline., Baseline through Week 18|Number of Participants That Improve or Remain Stable in MG ADL Total Score at Week 18 Compared to Baseline, Stable is defined as a ±3-point change from baseline., Baseline through Week 18|Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, Baseline up to Week 126 (8 weeks after last dose of study drug)|Number of Participants With Anti-Drug Antibody (ADA) at Week 18, Baseline through Week 18
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.